EC approves Menarini Group’s Orserdu for breast cancer treatment
Betsy Goodfellow | September 21, 2023 | News story | Medical Communications | European Commission, Oncology, Orserdu, breast cancer
The Menarini Group and its subsidiary Stemline Therapeutics have announced that the European Commission (EC) has approved Orserdu (elacestrant) as a monotherapy for the treatment of post-menopausal women and men with oestrogen receptor (ER)-positive, HER2-negative, locally advanced or metastatic breast cancer (mBC) with an activating ESR1 mutation who have experienced disease progression following at least one prior endocrine therapy.
This approval follows a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP), issued in July 2023. This approval means Orserdu becomes the first and only therapy specifically for this indication.
Data from the phase 3 EMERALD trial supports this approval, demonstrating statistically significant progression-free survival (PFS) with elacestrant compared to standard-of-care (SOC). Safety data remained consistent with previously reported information; the most common adverse events were nausea, an increase in triglycerides, increased cholesterol, vomiting, fatigue, dyspepsia, diarrhoea, decreased calcium, back pain, increased creatinine, arthralgia, decreased sodium, constipation, headaches, hot flushes, abdominal pain, anaemia, decreased potassium and increased alanine aminotransferase.
Elcin Barker Ergun, CEO of the Menarini Group, commented: “We have long known that patients living with metastatic breast cancer need effective and tolerable options which treat their disease while enabling them to focus on the things that matter to them. We are proud of delivering a new breast cancer treatment that offers efficacy in a once-daily pill and represents the first innovation in endocrine therapy in nearly two decades; we are also incredibly grateful for the support of the oncology researchers and all the patients who participated in the clinical studies that made today’s achievement possible.”
Betsy Goodfellow
Related Content
Sobi’s Aspaveli receives European Commission approval for treatment of two rare kidney diseases
Sobi has announced that its Aspaveli (pegcetacoplan) has received approval from the European Commission (EC) …
Bio-Sourcing and Zerion Pharma receive 1.3m euros in funding for joint breast cancer project
Bio-Sourcing and Zerion Pharma have announced that their collaboration to develop an oral form of …
Biocartis announces breast cancer research collaboration with US Mayo Clinic
Biocartis has announced a research collaboration with Mayo Clinic in the US, aiming to develop …
